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Abstract: In western Africa ethnomedicine, Lannea barteri Oliv. (Anacardiaceae) is believed to have
activity against gastrointestinal, neurological and endocrine diseases. Previous studies on this plant
have revealed antimicrobial, anticholinestrase, anticonvulsant, antioxidant and anti-inflammatory
activities. However, the anticancer potential of L. barteri has not been studied to date. The aim of
this study was to evaluate the anticancer potential of hot and cold extracts and silica gel column
chromatographic fractions of L. barteri leaf and stem bark. The extracts and fractions were tested
for anticancer activity by using the crystal violet cell proliferation assay on four adherent human
carcinoma cell lines—5637 (bladder), KYSE 70 (oesophagus), SiSo (cervical) and HepG2 (hepatic).
The inhibitory concentration (IC50) of fractions IH, 1I, 2E and 2F were: 3.75 ± 1.33, 3.88 ± 2.15,
0.53 ± 0.41, and 0.42 ± 0.45 µg/mL against KYSE 70 and 1.04 ± 0.94, 2.69 ± 1.17, 2.38 ± 3.64,
2.17 ± 1.92 µg/mL against SiSo cell lines respectively. Fraction 2E showed weak apoptotic activity
at double the IC50 and some sign of cell cycle arrest in the G2/M phase. Thus, phytoconstituents of
L. barteri leaf and stem bark can inhibit the proliferation of cancer cell lines indicating the presence of
possible anticancer agents in this plant.
Keywords: Lannea barteri; leaf; stem bark; adherent human carcinoma cell lines; 5637; KYSE 70;
SiSo; HepG2
1. Introduction
Medicinal plants used in folk medicine are a rich source of compounds with anticancer activities.
Studies of traditional medicine have resulted in pharmacological entities that have good efficacy
and different mechanisms of action from the existing orthodox medicines. It is believed that
phytoconstituents are good alternatives to conventional drugs used in the treatment of diseases
because they are inexpensive and may have less adverse effects [1]. Despite the growing concern about
these plant products due to their lack of standardization, they are in high demand by traditional care
givers for the treatment of various diseases including cancer. Thus, there are growing research interests
geared towards natural products for finding new drug entities from among the myriad of plant species
in African forests that are largely untapped. These efforts have often been successful since many plant
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materials have been found to have numerous and diverse pharmacological activities. Lannea barteri is
one of such plant that may be a source of anticancer agents.
L. barteri is a dioecious tree with a spreading crown; it can grow from 5–18 meters tall (Figure 1).
The bole is usually straight and clear of branches for several meters. It can be up to 40 cm in diameter
with a thick bark. Leaves are alternate, pinnately compound with 2–6 pairs of opposite leaflets and a
terminal cone, rachis 10–25 cm long, leaflets shortly stalked. Flowers are unisexual, regular, pedicel up
to 3 mm long, calyx-cupped shaped with lopes 1 mm long, ciliate, petals oblong yellowish with darker
veins. Fruits are compressed cylindrical drupe 10–13 mm × 7–8 mm glabrous, purplish red [2].
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Figure 1. Lannea barteri tree growing in Nigeria used in sample collection. 
Indeed L. barteri is widely used in western Africa in folk medicine. It is called sinsabega in 
Bimoba, mon in Dahomey Bassari, kuntunkuni in Ghana Akan-Asante, kuntunkurfi in Brong and in 
Ivory Coast Baule it is called kondro. It is known as faruhi in the northern part of Nigeria, and tiuko 
in Guinea [3]. L. barteri originates from East Guinea and is distributed in Ethiopia, Uganda, South of 
DR Congo, Nigeria, Mali, Burkina Faso, Ghana, Cote d’ Ivoire and Burundi [4,5]. The bark is 
frequently used as a stomachic. A decoction of the root is drunk as a treatment for gastric pains, 
diarrhoea, oedema, paralysis, epilepsy and madness [4]. When combined with the bark of Lannea 
kerstingii, it is used as a vermifuge [4]. The bark is used externally to treat ulcers, sores and leprosy. 
The root decoction is taken to cure hernias. The root is ground, wrapped in the leaves of an unknown 
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I ee L. barteri is widely used in western Africa in folk medicine. It is called sinsabega in Bimoba,
mon in Dahomey Bassari, kuntunkuni i Ghana Akan-Asante, kuntunkurfi in Brong and in Ivory Coast
Baule it is called kondro. It is known as faruhi in the nort er part of Nigeria, and tiuko in Guinea [3].
L. barteri originates from East Guinea and is distributed in Ethiopia, Uganda, South of DR Cong ,
Nigeria, Mali, Burkina Faso, Gha a, Cote d’ Ivoire and Burundi [4,5]. The bark is frequently used
as a stomachic. A decoction of the root is drunk as a treatment for gastric pains, diarrhoea, oedema,
paralysis, epilepsy and madness [4]. Whe co bi ed with the bark of Lannea kerstingii, it is used as a
vermifuge [4]. The bark is used externally to treat ulcers, sores and leprosy. The root decoction is taken
to cure hernias. The root is ground, wrapped in the leaves of an unknown species, and applied as
poultice on wounds. A leaf decoction is taken to cure haemorrhoids [6]. Phytochemical investigations
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on the stem bark and root of the plant have revealed the presence of saponins, coumarins, polyphenols,
alkaloids, tannins, quinones, steroids, terpenoids, and flavonoids [7,8]. Previous works on the stem
bark and root bark of L. barteri have revealed antimicrobial [7,8], anticholinesterase, DPPH radical
scavenging [7], anticonvulsant [9] activities, and on leaf extract antioxidant, hepatoprotective [10],
wound healing and anti-inflammatory activities [11]. Oxidative stress and chronic inflammatory
response have deleterious effect on macromolecules; thus, they can trigger different types of cancers.
Since the antioxidant and anti-inflammatory activities of this plant extract are good properties for cancer
prevention, and considering the link between oxidation and chronic inflammation to the development
of cancer, the need to explore the anticancer activity of this plant extract arose. The aim of this study
was to evaluate the anticancer potential of hot and cold extracts and column chromatography fractions
of leaf and stem bark of L. barteri on four adherent human carcinoma cell lines—5637 (bladder), KYSE
70 (oesophagus), SiSo (cervical) and HepG2 (hepatic) as well as the toxic effect of the extracts on
Artemia salina larva.
2. Results
2.1. Yield of Extracts and Fractions
The extraction processes yielded hot (h) and cold (c) dichloromethane (DCM) (DLEh, DLEc,
DSbEh, DSbEc), methanol (MLEh, MLEc, MSbEh, MSbEc) and water (WLEh, WLEc, WSbEh, WSbEc)
extracts. The yields of the various extracts are shown in Table 1. The thin layer chromatography (TLC)
of DLEc and DSbEc gave different spots with varying retention factors (Table 2). Similarly, fractionation
of the DLEc and DSbEc by silica gel column chromatography yielded 11 fractions (1A–1K) from DLEc
and 10 fractions (2A–2J) from DSbEc (Table 3).
2.2. Phytochemical Constituents of Extracts and Most Active Chromatography Fractions
Phytochemical analysis on the DLEc and DSbEc gave positive reactions for terpenoids and
steroids, respectively.
Table 1. Yield of L. barteri leaves and stem bark extracts.
Extract Yield
mg %
DLEc 40.1 1.86
DSbEc 46.1 1.15
DLEh 235.2 2.35
DSbEh 216.1 2.37
MLEc 195.0 9.75
MSbEc 78.5 3.93
MLEh 748.7 17.49
MSbEh 912.0 10.03
WLEc 90.4 4.52
WSbEc 47.0 2.35
WLEh 718.8 7.17
WSbEh 227.3 2.27
DLEc—cold dichloromethane (DCM) leaf extract, DSbEc—cold DCM stem bark extract, DLEh—hot DCM leaf
extract, DSbEh—hot DCM stem bark extract, MLEc—cold methanol leaf extract, MSbEc—cold methanol stem bark
extract, MLEh—hot methanol leaf extract, MSbEh—hot methanol stem bark extract, WLEc—cold water leaf extract,
WSbEc—cold water stem bark extract, WLEh—hot water leaf extract and WSbEh—hot water stem bark extract.
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Table 2. TLC retention factor (Rf) values of the most active extracts.
Solvent Ratio
(n-hexane: ethyl acetate) DLEc DSbEc
Rf
9:1 0.25 0.30
8:2 0.38 0.32
7:3 0.47 0.50
6:4 0.50 0.55
5:5 0.68 0.70
4:6 0.44 0.38
3:7 0.40 0.30
2:8 0.26 0.28
1:9 0.22 0.25
DLEc = cold DCM leaf extract; DSbEc = cold DCM stem bark extract.
Table 3. Yield of fractions from chromatography of cold DCM leaf and stem bark extracts.
Fractions PooledSamples Weight (mg)
Yield
(%)
1A 8–13 3.30 0.66
1B 14–20 15.50 3.10
1C 21–28 27.80 5.56
1D 29–37 13.40 2.68
1E 38–42 113.70 22.74
1F 43–47 31.70 6.34
1G 48–56 13.60 2.72
1H 57–85 14.90 2.98
1I 86–102 7.80 1.56
1J 103–187 41.00 8.20
1K 188–192 39.40 7.00
2A 1–7 8.20 1.64
2 B 8–24 9.30 1.86
2 C 25–40 13.00 2.60
2 D 41–44 29.60 5.92
2 E 45–51 48.20 9.64
2 F 52–61 69.80 13.96
2 G 62–77 59.50 11.90
2 H 78–105 54.10 10.82
2 I 106–109 84.00 16.80
2 J 110–140 8.80 1.76
(1A–K) and (2A–J) represent fractions from DLEc and DSbEc respectively.
2.3. The RP-HPLC Chromatograms of the Active Fractions from the Cold DCM Extracts of Leaf (1E–1J) and
Stem Bark (2D–2I)
The chromatograms of the active fractions from the cold DCM extracts of leaf (1E–1J) and stem
bark (2D–2I) revealed absorption peaks (Au) of different heights at varying wavelengths between
(210-600 nm) and retention times. The chromatogram of fraction 1E revealed five prominent peaks
between retention times 24 and 32 min (Figure S1). Fraction 1F gave eight peaks with two prominent
peaks occurring at 29.20 and 31.01 min (Figure S2). Fraction 1G gave a total of six peaks with three
major sharp peaks at 28.72, 29.19 and 30.96 min retention times (Figure S3). Fraction 1H gave nine
major peaks with the first three peaks well separated from one another at retention times of 13.25, 14.83
and 16.61 min; also, the eighth peak was very sharp at retention time of 39.37 min (Figure S4). Fraction
1I had two major peaks occurring at retention times of 28.72 and 30.64 and clusters of other peaks
(Figure S5). Fractions 1J and 1K had similar peaks with two major peaks occurring at 20.73/20.64 min
and 30.73/30.56 min respectively and with clusters of other minor peaks (Figures S6 and S7).
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Fraction 2D gave three peaks with one sharp peak which eluted at 24.75 min (Figure S8). Fraction
2E gave five peaks, two sharp peaks and other broad peaks (Figure S9). Fraction 2F gave three
prominent and well–separated sharp peaks at 18.96, 23.73 and 31.87 min with two additional minor
peaks (Figure S10). Fraction 2G gave seven peaks some of which were well separated (Figure S11)
while fraction H gave two broad peaks and one sharp peak which occurred at 27.41 min (Figure S12).
Fraction 2I gave only one broad peak that eluted at 14.67 min (Figure S13).
2.4. Effect of Extracts of on 5637, KYSE 70 and SiSo Cancer Cell Lines Proliferation in Primary Screening
DLEh and DSbEh inhibited the proliferation of all the cancer cell lines while the MLEh, MSbEh,
WLEh and WSbEh showed no growth inhibition. The (T/C) corr. (%) values of DLEh, MLEh, MSbEh,
WLEh and WSbEh for the various cancer cell lines are shown in Table 4.
DLEc and DSbEc extracts inhibited the proliferation of all the cancer cell lines tested while
MLEc and MSbEc inhibited 5637 and SiSo cell lines only. The WLEc and WSbEc did not inhibit the
proliferation of any of the cancer cell lines. The T/C corr. (%) values for the extracts that had activity are
shown in Table 4.
The order of antiproliferation activity of DLEc and DSbEc on the cell lines was SiSo> KYSE 70 > 5637.
The extracts with T/C corr. values less than 50% were thus selected for secondary screening.
Table 4. Antiproliferative activity T/C corr. (%) of extracts (50 µg/mL) on 5637, KYSE 70 and SiSo cell
lines in primary screening.
Extract Cell Line
5637 KYSE 70 SiSo
T/C corr. (%)
DLEc 14.76 5.83 4.62
DSbEc 7.82 3.03 2.56
DLEh 2.01 5.18 4.21
DSbEh -3.12 4.63 2.67
MLEc 1.77 >50 20.95
MSbEc 3.64 >50 24.33
MLEh >50 >50 >50
MSbEh >50 >50 >50
WLEc >50 >50 >50
WSbEc >50 >50 >50
WLEh >50 >50 >50
WSbEh >50 >50 >50
Stock solution concentration = 50 µg/mL DMSO, n = 2; DLEc—cold DCM leaf extract, DSbEc—cold DCM stem
bark extract, DLEh—hot DCM leaf extract, DSbEh—hot DCM stem bark extract, MLEc—cold methanol leaf extract,
MSbEc—cold methanol stem bark extract, MLEh—hot methanol leaf extract, MSbEh—hot methanol stem bark
extract, WLEc—cold water leaf extract, WSbEc—cold water stem bark extract, WLEh—hot water leaf extract and
WSbEh—hot water stem bark extract; T/C corr.—treated versus control corrected.
2.5. Effects of Extracts on KYSE 70 and SiSo Cell Lines in Secondary Screening
The IC50 values of the hot extracts (DLEh, DSbEh. MLEh and MSbEh) against the KYSE 70 and
SiSo cell lines are shown in Table 5. The DSbEh inhibited growth of both cell lines more than the DLEh.
The MLEh inhibited only the SiSo cell line while the MSbEh inhibited the growth of none of the cancer
cell lines (Table 5).
The growth inhibitory effect of the DSbEc on the KYSE 70 and SiSo were significantly (p < 0.05)
higher than that of DLEc. The MLEc significantly (p < 0.05) inhibited the SiSo cell line more than the
MSbEc (Table 5).
The comparison of the cell proliferative inhibitory activity of the hot and cold DCM extracts on
the KYSE 70 cell line showed no significant difference between DLEh and DLEc, and between DLEh,
DLEc and DSbEh; but there was significant (p < 0.05) difference between DLEh, DLEc and DSbEc with
DSbEc showing the highest inhibitory activity (Figure 2A). There was no significant difference in the
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growth inhibitory activities of SiSo cancer cell line by the leaf and stem bark extracted with hot and
cold DCM (Figure 2B).
Table 5. IC50 of extracts on KYSE 70 and SiSo cell lines in secondary screening.
Extract Cell Line
KYSE 70 SiSo
IC50 (µg/mL)
DLEc 11.03 ± 2.68 12.06 ± 8.39
DSbEc 2.26 ± 0.92 6.37 ± 2.15
DLEh 12.23 ± 3.12 10.68 ± 2.36
DSbEh 5.28 ± 3.43 5.62 ± 3.00
MLEc >50 11.01 ± 4.04
MSbEc >50 23.85 ± 9.41
MLEh >50 20.93 ± 4.09
MSbEh >50 >50
Stock solution concentration = 50 µg/mL DMSO for DLEh, DSbEh, MLEc, MSbEc, MLEc and MSbEh, 25 µg/mL
DMSO for DLEc and DSbEc. n = 3; DLEc—cold DCM leaf extract, DSbEc—cold DCM stem bark extract, DLEh—hot
DCM leaf extract, DSbEh—hot DCM stem bark extract, MLEc—cold methanol leaf extract, MSbEc—cold methanol
stem bark extract, MLEh—hot methanol leaf extract, MSbEh—hot methanol stem bark extract, WLEc—cold water
leaf extract, WSbEc—cold water stem bark extract, WLEh—hot water leaf extract and WSbEh—hot water stem
bark extract.
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Figure 2. Comparison of IC50 of hot and cold DCM and methanol extracts of leaf and stem bark against
KYSE 70, SiSo, HepG2 and 5637 cell lines. (A) = KYSE 70 cell line, (B,C) = SiSo cell line, (D) = HepG2
cell line, (E) = 5637 cell line. Values are mean ± SEM (n = 3) one-way ANOVA. (Tukey’s multiple
comparisons test). DLEc—cold DCM leaf extract, SbEh—hot DCM stem bark extract, MLEc—cold
methanol leaf extr ct, MSbEc— old methanol s bark extract, MLEh—hot methanol leaf extract.
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There was no significant difference in the growth inhibitory activity of MLEh, MLEc and MSbEc
on SiSo cell line. MLEc produced significantly (p < 0.05) higher inhibitory activity on SiSo cancer cell
line when compared to MSbEc (Figure 2C).
On the HepG2 cancer cell line, both the hot and cold DCM extracts of the leaf and stem bark
inhibited the proliferation of this cell line (Figure 2D). DSbEh and DSbEc significantly (p < 0.001)
inhibited the proliferation of HepG2 cancer cell line. When compared, DLEh and DLEc did not produce
as much inhibition of HepG2 cancer cell line proliferation as DSbEh and DSbEc. Their IC50 values of
the inhibition of the various cancer cells proliferations are shown in shown in Figure 2D.
The cold and hot DCM leaf and stem bark extracts inhibited the proliferation of 5637 with lower
IC50 values (Figure 2E). The inhibitory activities against 5637 were significantly (p < 0.05) higher with
DSbEh and DSbEc compared to DLEh and DLEc (Figure 2E).
2.6. Effect of Column Chromatography Fractions of DLEc (fractions 1A–K) and DSbEc (fractions 2A–I) on
5637, KYSE 70, SiSo and HepG2 Cell Lines Proliferation in Primary Screening
After screening the various extracts for anticancer activity, those extracts with biological activity
(e.g., DLEc, DSbEc) were subject to silica gel column chromatography and the collected fractions
again screened for anticancer activity. The results showed that fractions 1E and 2F produced a higher
inhibitory effect on the proliferation of 5637 of cell lines than the other fractions tested (Table 6).
Fractions 1H and 2E produced remarkable proliferation inhibition against KYSE 70 cell line (Table 6);
fractions 1D and 2E inhibited the proliferation of SiSo cell line to a greater extent compared to the
inhibition produced by other fractions (Table 6) while fractions 1H, 2D and 2H inhibited the proliferation
of HepG2 cell line largely compared to other fractions (Table 6).
Table 6. Antiproliferative activity as T/C corr. (%) of fractions (50 µg/mL) on 5637, KYSE 70, SiSo and
HepG2 cell lines.
Fraction Cell line
5637 KYSE 70 SiSo HepG2
T/C corr. (%)
1A 33.67 85.26 108.84 99.21
1B 3.06 62.12 100.00 20.58
1C 3.06 69.29 116.02 44.33
1D −9.18 61.57 −10.50 37.99
1E -11.22 −0.22 −4.18 −7.39
1F −1.02 −2.22 −4.50 −10.95
1G −9.66 −2.95 −6.75 −12.40
1H −6.90 −4.15 −6.59 14.25
1I −7.38 −4.04 −6.27 14.12
1J −8.18 −3.82 −6.11 14.38
1K 15.54 −4.42 −2.73 10.55
2A 22.94 71.51 23.79 83.51
2B −14.94 51.64 21.57 48.15
2C −16.91 12.01 6.11 −1.58
2D −16.21 −4.91 −0.07 −14.64
2E −15.01 −5.13 −7.24 −14.51
2F −17.01 −4.80 −7.07 −14.51
2G −13.91 −5.02 −6.43 −13.98
2H −8.91 −4.80 −6.01 −14.64
2I −13.17 −4.04 −5.95 −11.21
2J −9.34 62.55 22.51 10.82
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2.7. Effect of Column Chromatography Fractions of DLEc (Fractions 1E–1K) and DSbEc (Fractions 2D–2I) on
KYSE 70 and SiSo and HepG2 Cell Lines Proliferation in Secondary Screening
Secondary screening was done on the various active fractions to estimate IC50 values. The IC50
value of fractions 1H (3.75 µg/mL) and 1I (3.88 µg/mL) were significantly (p < 0.001) lower than that of
fraction 1K (20.21 µg/mL) when inhibition of cell proliferation produced by all the fractions against
KYSE 70 cell line were compared (Figure 3A). Similarly, the IC50 values of fractions 1G (9.77 µg/mL) and
1J (8.22 µg/mL) were significantly lower than that of fraction 1K while the IC50 values of fractions 1E
(10.37 µg/mL) and IF (11.89 µg/mL) were lower than that of fraction K but not significantly (Figure 3A).Molecules 2020, 25, x  9 of 19 
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Figure 3. IC50 values of fractions 1E-1K and 2D–2I from DLEc and DSbEc respectively against the
cell lines. (A,B) = KYSE 70 cell line, (C,D) = SiSo cell line and (E,F) = HepG2 cell line. Values are
mean ± SEM (n = 3) one-way ANOVA (Tukey’s multiple comparisons test).
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The IC50 values in µg/mL for these fractions were 5.77 (2D), 0.53 (2E), 0.42 (2F), 6.05 (2G), 7.76 (2H)
and 15.58 (2I). There was significant (p < 0.0001) difference between the IC50 of fractions 2E and 2F
compared to fraction 2I on their inhibition against KYSE 70 (Figure 3B). There was significant (p < 0.01)
difference in the IC50 values of fractions 2D and 2G in comparison to that of fraction 2I while the IC50
of fraction 2F significantly (p < 0.05) differed from that of fraction 2H just as the IC50 of fraction 2H
significantly (p < 0.05) differed from that of fraction 2I (Figure 3B).
The leaf fractions inhibited the proliferation of SiSo cell line to varying extent. Significant (p < 0.05)
inhibition of SiSo cell line proliferation were recorded with fractions 1F, 1H, 1I, 1J and (p < 0.01) with
fraction 1H compared to fraction 1K (Figure 3C).
There was no significant difference in the IC50 values of the stem bark fractions that inhibited the
proliferation of SiSo cell line when compared with the various treatments (Figure 3D).
The proliferative inhibitory activity of fractions 1H and 1I against HepG2 cell line were significant
(p < 0.05 and p < 0.001) when compared to fractions 1E and IK respectively; they had the lowest IC50
values of 0.25 and 0.30 µg/mL respectively when all the treatment groups were compared (Figure 3E).
Fractions 2E and 2F had the lowest IC50 values (8.8 × 10−4 and 2.06 × 10−4µg/mL, respectively)
when compared with other fractions (2D, 2G, 2H, and 2I) against HepG2. The inhibitory effect of the
2E and 2F fractions against the proliferation of HepG2 cell line were significant (p < 0.01) compared to
fraction 2I (Figure 3F).
2.8. Effect of Column Chromatography Fractions 1H, 1I 2E, 2F on Apoptosis Induction in SiSo Cancer Cell Line
The percentage of apoptotic cells induced by the fractions and DMSO at IC50 value after 24 h and
48 h incubation periods respectively were 22.34%, 15.51% (DMSO), 19.9%, 16.38% (1H), 18.52%, 11.58%
(1I), 31.09%, 11.74% (2E), 30.87% and 15.30% (2F) (Figure 4). At concentrations doubled the IC50 values,
the percentage of apoptotic cells induced by the fractions and DMSO at 24 h and 48 h incubation periods
were 20.25%, 16.79% (DMSO), 31.16%, 14.19% (1H), 19.95%, and 17.25% (1I), 47.07%, 34.00% (2E),
27.85% and 25.83% (2F) respectively. From this result, fraction 2E gave the highest fractions (47.07%
and 34.00%) of apoptotic cells at doubled the IC50 concentration after 24 h and 48 h incubation periods,
respectively, compared with other fractions and control. Meanwhile, the leaf fractions especially
fraction 1I had the highest number (0.68 and 1.22%) of necrotic cells than the stem bark fractions at
doubled the IC50 concentration after those incubation periods.
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2.9. Effect of Fractions 1H, 1I 2E, 2F on Cell Cycle Progression in SiSo Cancer Cell Line
In the cell cycle measurement, there was a non-significant reduction in the population of cells
(50.39%) in the G1/G0 phase with concomitant increase in the population of cells accumulated in S
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(24.78%) and G2/M (20.04%) phases especially at doubled the IC50 concentration of fraction 2E at
48 h incubation period compared to control (Figures 5 and 6). Fraction 1H accumulated the highest
percentage (21.28%) of cell population at G2/M phase followed by fraction 1I (20.47%) at doubled the
IC50 value after 24 h incubation period eventhough these changes were not significant (Figures 5 and 6).Molecules 2020, 25, x  11 of 19 
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2.10. Toxic effect of Extracts on Brine Shrimp
To test for general toxicity of the extracts in vivo, the brine shrimp assay was used. In this assay,
the lethal concentration at 50% of the population (LC50) of the DLEc was found to be 5649.20 µg/mL
while the extrapolated effective concentration was 564.92 µg/mL. However, the LC50 of DSbEc was
124.78 µg/mL while the EC50 was 12.48 µg/mL. At 1000 µg/mL, the percentage death was high (66.7%)
with DSbEc and low (13.3%) with DLEc. The calculated therapeutic index (TI) for both extracts was
9.99 (Table 7).
Table 7. Toxic effect of extracts on brine shrimp.
Treatment Dose(µg/mL) Alive Dead
Dead
(%)
DLEc 10 29 1 3.3
100 25 5 16.7
1000 26 4 13.3
10% Tween 80 - 30 - 0
DSbEc 10 17 13 43.0
100 11 19 63.3
1000 10 20 66.7
The estimated LC50 were 5649.20 µg/mL (DLEc) and 124.78 µg/mL (DSbEc); EC50 were 564.92 µg/mL (DLEc) and
12.48 µg/mL (DSbEc) and therapeutic index (TI) was 9.99 for both. LC50 and EC50—lethal and effective concentrations
at 50% population respectively, DLEc—cold DCM leaf extract, DSbEc—cold DCM stem bark extract, n = 30.
3. Discussion
Cancer is a life-threatening and difficult-to-manage disease that ultimately overwhelms the entire
bodily functions of the patient. This disease requires a multi-disciplinary approach to identify new
pharmacological entities that will result in success and give strong and positive hope to the patient and
the care giver. Some cancers can be cured completely when detected early either with chemotherapeutic
agents, surgery, ionization therapy or a combination of two or more of these treatment options. Over
the years, researchers have searched for new lead pharmacological compounds either from plants
or other biological products that can be better than the existing drugs in terms of efficacy and safety.
Certain plants have been investigated for their anticancer potentials and some of the plant materials
have been found effective as anticancer agents. One such plant that interested us is Lannea barteri,
a plant native to some African countries. This study investigated the anticancer potential of L. barteri
leaf and stem bark extracts and fractions on four adherent human cancer cell lines: KYSE 70, SiSo, 5637
and HepG2 by using the crystal violet cell proliferation assay as a bioactivity guide [12]. Furthermore,
the cytotoxic effect of DLEc and DSbEc on brine shrimp and the mechanism of anticancer activity of
the fractions were studied. The phytoconstituents - terpenoids and steroids were present in DLEc and
DSbEc, respectively.
Proliferation in cells is favored when there is phosphorylation of specific regulatory proteins by
cyclin–dependent kinases, the engine that makes the cell cycle run [13]. Adherent cells detach from
cell culture plate during cell death and this characteristic could be used for the indirect quantification
of cell death and to find differences in proliferation upon stimulation with death-inducing agents [14].
Simple screening methods to detect maintained adherence of cells are the staining of the attached cells
with either crystal violet, neutral red or sulforhodamine B dyes. Crystal violet binds to proteins and
DNA. When cells undergo cell death they detached from cell culture plate and the amount of crystal
violet staining is reduced [15]. Indeed, some of the extracts and fractions with cytotoxic activity were
able to reduce the color intensity of crystal violet, showing inhibition of cell proliferation and marked
cell death at low concentrations (< 30 µg/mL).
Primary screening of plant materials for anticancer activity with the crystal violet assay is a
standard method for selecting choice pharmacological products for secondary screening to enable
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testing at range of doses [12]. The primary screening was designed to assess the threshold for cell
growth inhibition produced at one concentration of extract (e.g., 50 µg/mL), enabling only extracts
which satisfy the threshold inhibition criteria to progress to the 5-dose screening designed to capture
efficiently the compounds with antiproliferative activity in the form of IC50 values [16].
The results of primary screening revealed that the DCM and methanol extracts were cytotoxic to
the cell lines at concentrations below 50 µg/mL and thus were subjected to secondary screening.
L. barteri hot and cold extracts and silica gel chromatography fractions showed strongest
antiproliferative activity against KYSE 70, SiSo, 5673 and HepG2 cancer cell lines at very low IC50
values. The DSbEh and DSbEc gave more inhibition against all the cell lines than DLEc while the
MLEc inhibited 5637 and SiSo cell lines more than the MSbEc. This activity increased with column
fractionation of the extracts. There was a selective activity of extract and fractions from the stem bark
for the KYSE 70 cell line more than those from the leaf, suggesting its efficacy in oesophageal squamous
cell carcinoma [17].
SiSo is a human cancer cell line which was established from a patient afflicted with uterine cervical
adenocarcinoma. The growth of SiSo cell line was markedly inhibited by the cold dichloromethane
extracts which increased with fractionation. The DLEc and its fractions had more inhibitory effect on
SiSo and high selectivity for this cell line than other extracts and fractions.
Brine shrimp lethality assay is an essential tool used for preliminary assessment of toxicity of
medicinal plant products by measuring their potentials to kill larvae of Artemia salina leach [18]. It is
an all-or-none method of assay. The lethal concentration (LC50) of the DLEc that killed the 50% of the
population of the larvae was higher than the concentration of DSbEc that killed the same percentage of
the population. The concentration of the DLEc effective at 50% of the population (EC50) was higher
than that of DSbEc even though they had the same therapeutic index. The EC50 of a quantal dose
response curve represents the concentration of a compound where 50% of the population exhibits a
response after a specific exposure time. It also measures the potency of substances [19]. Therefore, the
stem bark extract with lower EC50 and LC50 values was more potent as toxic agent than the leaf extract.
Assessment of the mechanism of cytotoxic activity of the most active fractions from the leaf and
stem bark extracts of L. barteri revealed some level of apoptotic activity and cell cycle arrest. Apoptosis
is a form of programmed cell death in multicellular organisms that involves biochemical cascade of
events leading to morphological changes such as (blebbing, cell plasmolysis, nuclear fragmentation,
chromatin condensation and chromosomal DNA fragmentation) and eventual death without affecting
the normal cell [20]. Apoptosis can be initiated by anticancer drugs, gamma and ultraviolet irradiation,
deprivation of survival factors such as interleukin-1, and several other cytokines that activate “death
receptors” such as Fas and tumour necrosis factor receptors [20]. Fraction 2E had higher apoptosis
induction potential than other fractions. This was evident with the greater percentage of fractions
of annexin V positive cells than those that are positive to both annexin V and propidium iodide
(PI). Annexin V binds to phosphatidyl serine on the extracellular surface of the cell membrane while
propidium iodide binds DNA of only cells that have lost their membrane integrity. However, living
cells with intact cell membrane do not stain positive to PI, and cells that are positive to Annexin V
and PI are considered dead while those only positive to Annexin V are considered to be undergoing
apoptosis [21,22].
The cell cycle is a physiological process that occur in distinct stages to assure controlled cell
growth, development and division. Cell proliferation and differentiation are under tight genetic control
in normal cells. For cancer to arise there is altered control in the genetic machinery that controls cell
proliferation and eventual progression of stages of cell cycle which is the hallmark of cancer growth
and sustenance [23]. Cell cycle analysis by DNA content measurement is a method that most often
employs flowcytometry to distinguish cells in different phases of the cell cycle and quantification of
intracellular components especially DNA, as well as cell cycle-related metabolic molecules such as
cyclin-dependent kinases and cyclins [23]. The fractions showed non-specific cell cycle arrest with
fraction 2E showing the greatest accumulation of DNA at G2/M phase and corresponding decrease
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in G1/G0 phase in SiSo cancer cell line. This suggests that fraction 2E may be arresting the cell cycle
progression at this stage implying that DNA damage may be partly involved in the cell death.
In conclusion, our findings show that the cold DCM extracts and fractions from the Lannea barteri
leaf and stem bark possess potent anticancer activity against 5637 (urinary bladder), KYSE 70
(oesophageal squamous), SiSo (cervix adeno-) and HepG2 (hepatocellular) human carcinoma cell lines.
The stem bark extract showed greater activity than the leaf extract. It would appear that apoptosis and
cell cycle arrest at G2/M phase are likely anticancer mechanisms of action. The anticancer activity may
be attributed to unknown phytoconstituents inherent in the plant. Work is ongoing to purify the most
active fraction, isolate and characterize the compound(s) that have the anticancer activity, to test them
on other cancer cell lines and to explore other possible mechanism(s) of cytotoxic activity.
4. Materials
4.1. Equipment and Apparatuses
Digital and electronic weighing balance (Satorius® Entris, BP 21005, Goettigen, Germany),
ultrasonicator (Bandelin Sonopuls UW 2070®, Berlin, Germany), magnetic stirrer (Heidolph models
MR® 3000 and MR 3001, Schwabach, Germany), rotary evaporator (Buchi Rotavapor®, R-200 and
R-210, Duisburg, Germany) with heating bath (Buchi heating bath®, B-490 and B-491, ), folded
qualitative filter paper 301 size 185 mm with particle retention size of 12–15 µm, flasks (conical and
round bottom), measuring cylinders, mechanical grinding machine, refrigerator of−20◦C, lyophilizer,
analytical TLC plates (silica gel 60 F254, 20 × 20) and silica gel (Kieselgel 60 H, 70–230 mesh, Merck,
Darmstadt, Germany), VLM EVA 2® Evaporator (VLM GmbH, Bielefeld, Germany), column fractions
retriever, 96–well microtiter plates and25 mL and 75 mL flasks (Sarstedt, Nümbrecht, Germany),
8- and 12- channel–pipette (Labopette 50–250 µL, Hirschmann®, Eberstadt, Germany), centrifuge
(Heraeus Biofuge primo R) and incubator (Heracell, ThermoFisher Scientific, Waltham, M.A, USA),
particle counter and size analyzer (Coulter Z2, Beckman Coulter, Fullerton, CA, USA), sterile filters
(PAN® Biotech GmbH, Aidenbach, Germany), universal shaker, (Lab Tec Edmund BühlerGmbH TiMix,
Hechingen, Germany), HPLC system (Merck-Hitachi LaChrom, Fukuoka, Japan), microtiter plate
reader (SPECTRAmax Plus, Molecular Devices, San Jose, CA, USA) and flow cytometer (MACS Quant
Analyzer, Miltenyi Biotec, Teterow, Germany).
4.2. Chemicals and Solvents
All solvents were analytical grade and water was purified either by distillation or with an
Elga PureLab Flex4 (Veolia Water Tech, Celle, Germany), penicillin/streptomycin solution (10,000U
penicillin/mL, 10 mg streptomycin/mL), RPMI-1640 culture medium® and L-glutamine (PAN Biotech,
Aidenbach, Germany), ribonuclease-A (Rnase) and NaHCO3 (Carl Roth GmbH, Karlsruhe, Germany),
50% glutaraldehyde solution, trypsin—EDTA solution and fetal calf serum (FCS) (Sigma-Aldrich,
Munich, Germany), HPLC gradient acetonitrile (ACN) (VWR International, Darmstadt, Germany),
Dulbecco’s buffer (pH 7.4): KCl—0.2 g/L, NaCl—8 g/L, MgSO4.7H2O—0.1 g/L, KH2PO4—0.2 g/mL,
Na2HPO4.7H2O—1.55 g/mL, AnnexinV apoptosis kit (Miltenyi Biotec, Teterow, Germany), propidium
iodide (Applichem, Darmstadt, Germany), phosphate buffered saline (PBS), Triton X-100 (Merck,
Darmstadt, Germany).
4.3. Cancer Cell Lines
KYSE 70, SiSo, 5673 and HepG2 human cancer cell lines were obtained from the German Collection
of Microorganisms and Cell Culture (DMSZ Braunschweig, Germany).
4.4. Brine Shrimp Larvae
Artemia salina larvae were obtained from Department of Veterinary Pharmacology, Faculty of
Veterinary Medicine, University of Nigeria, Nsukka.
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5. Methods
5.1. Plant Collection and Preparation
The fresh leaves and stem bark of Lannea barteri were collected from Benue State, Nigeria in
the months of March and April by Mr. Alfred Ozioko of International Centre for Drug Discovery
and Development and the specimen voucher (Voucher No: 096) deposited at the Centre’s herbarium.
The plant materials were dried under shade, and subsequently pulverized into powder for future use.
5.2. Distillation of Solvents Used for Extraction and Fractionation
All extraction solvents were distilled to their pure states according to their specific boiling points:
65◦C (methanol), 39.8◦C (dichloromethane (DCM)), 59◦C (ethyl acetate) and 69◦C (n-hexane).
5.3. Cold Extraction of the Plant Materials
About 2 g each of the powdered material were subjected to successive cold extraction by using
the following solvents in increasing order of polarity; DCM, methanol and water. The powdered
material was soaked in about 100 mL solvent in a conical flask and then sonicated for 10 min in an
ice pack to break the cell wall of the plant biomass. Afterwards, the flask was placed on a magnetic
stirrer for 180 min at 250 rpm. The content of the flask was centrifuged at 3500 rpm for 10 min and the
supernatant filtered into a round bottom flask. The extraction process was repeated two more times
after which the filtrates were pooled together and evaporated by using a vacuum rotary evaporator in
a fume hood according to the boiling pressure of the solvent: 880 mbar (DCM), 337 mbar (methanol)
and 72 mbar (water) at 50◦C. After extraction with each solvent, the marc was dried overnight in a
fume hood before the next solvent was used until the last solvent. The concentrated extracts yielded
cold (DCM) leaf (DLEc) and stem bark (DSbEc) extracts, cold methanol leaf (MLEc) and stem bark
(MSbEc) extracts and cold water leaf (WLEc) and stem bark (WSbEc) extracts which were weighed,
yield in (%) calculated and stored in the refrigerator for future use.
The extracts were subjected to anticancer screening by the crystal violet cell proliferation assay as
a bioactivity guide (see below).
5.4. Sohxlet (hot) Extraction of the Plant Materials
About 10 g of the plant material was extracted successively with these solvents in the increasing
order of polarity according to their boiling temperatures 39.8◦C (DCM), 65◦C (methanol), and 100◦C
(water) in continuous extraction for 12 h by using a Sohxlet extraction apparatus. After extraction with
each solvent, the marc was dried overnight in a fume hood before the next solvent was used until the
last solvent. The extracts were concentrated using rotary evaporator as described in Section 5.3 to
yield hot DCM leaf (DLEh) and stem bark (DSbEh) extracts, hot methanol leaf (MLEh) and stem bark
(MSbEh) extracts and hot water leaf (WLEh) and stem bark (WSbEh) extracts. These extracts were
weighed, yield in (%) calculated and stored in the refrigerator for future use.
The extracts were subjected to anticancer screening by the crystal violet cell proliferation assay as
a bioactivity guide (see below).
5.5. Thin Layer Chromatography (TLC) of the Most Active Extract
The DSbEc and DLEc which exhibited the greatest antiproliferative activity were subjected to
TLC by using 1:1 ratio of analytical grade n-hexane and ethyl acetate and the retention factors were
calculated [24].
5.6. Column Chromatography of DLEc and DSbEc with Gradient Elution Method
The DLEc and DSbEc were subjected to column fractionation on 60 H 70–230 mesh silica gel
by using gradient elution method with these respective solvent combination ratios (9:1 (200 mL), 1:1
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(200 mL), 2:8 (200 mL)) of analytical grade n-hexane and ethyl acetate; and lastly 100% methanol
(100 mL). The resulted fractions (1A-K from DLEc and 2A-2J from DSbEc) were further subjected to
primary screening with the crystal violet cell proliferation assay. The seven fractions (1E-K) from DLEc
and six fractions from DSbEc (2D-I) that gave the lowest T/C corr. (%) values were selected for secondary
screening using crystal violet cell proliferation assay and determination of IC50. The fractions were
then subjected to HPLC analysis.
5.7. High Performance Liquid Chromatographic (HPLC) Separation
The cytotoxic fractions (50 mg/mL) mentioned in Section 5.6 were subjected to reversed phase
HPLC analysis with the following conditions: 10 µL were injected onto a 250 × 4 mm Nucleodur
PolarTec (5 µm) column (Macherey-Nagel, Dueren, Germany) held at 30◦C and eluted with a solvent
mixture containing 10 mM (pH =3.3) phosphate buffer (PB) and acetonitrile (ACN) at a flow rate of
0.7 mL/min according to the following program:: – 80:20PB/ACN for 5 min, linear gradient to 20:80
PB/ACN over 20 min, 20:80 PB/ACN for 10 min. Detection was done with a diode array UV/vis detector
set to scan wavelengths between 210–600 nm and monitoring at 250 nm for a period of 35 min.
5.8. Phytochemical Analysis of DLEc and DSbEc
The DLEc and DSbEc were screened for the presence of bioactive components following the
methods of [25,26].
5.9. BiologicalStudies
5.9.1. Crystal Violet cell Proliferation Assay
The crystal violet cell proliferation assay was used as a bioactivity guide in both primary and
secondary screening assays as previously described [27,28]. To prepare the 96–well microtiter plates,
the cell cultures were first treated with trypsin-EDTA to obtain a cell suspension. Then, 100 µL of the
cell suspensions were seeded at a density of 1000 cells per well for each cancer cell line. The plates
were incubated for 24 h before treatment with the extract samples. Following treatment (see below),
the cells were incubated 96 h, cell growth was stopped by replacing the culture medium with 1%
glutaraldehyde buffered saline (GBS) for 20 min and then stored under Dulbeccos’s buffer solution.
Later, the buffer solution was removed and the cells were stained with 0.02% crystal violet in deionized
water (100 µl per well) for 30 min. Thereafter, the excess dye was discarded and the plates washed
in water for 30 min. The cell–bound dye was re–dissolved with 70% ethanol (100 µl per well) and
the plates were placed on the microtiter shaker for 2 h before the optical density (OD) was read at
λ = 570 nm with a microtiter plate reader. The corrected percent growth values, e.g., Treated versus
Control corrected percentage (T/C) corr. (%) was calculated with the equation:
(T/C) corr. (%) = (ODT − ODC,0)/(ODC − ODC,0) × 100
where ODT is the mean OD of the treated cells, ODC the mean OD of the controls, and ODC,0 the mean
OD of seeded cells at the time the drug was added.
The IC50 (half maximal inhibitory concentration) values were estimated by linear least – square
regression of the (T/C) corr. (%) by using MS Excel® function trend values versus the logarithm of
the concentration of extract. The concentration that showed (T/C) corr. values between 10% and 90%
were used in the calculation. The reported IC50 values are the average of 3 independent experiments.
The IC50 value indicated the potency of the extract and equaled the amount of complex that inhibited
the cell growth by 50%. The lower the IC50 value the greater the potency of the extract.
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Primary Screening
Cells were treated with stock solution of the extracts dissolved in DMSO at 50 mg/mL; a 10µL of the
stock solution was added to 5.0 mL of RPMI medium containing 10% FCS and 1% penicillin/streptomycin
solution, of which 100 µL of the solution was added to each well to give final concentrations of 50 µg/mL
extract mass.. One plate was left untreated for each cell line and this served later as the control (C) at
time zero (0) (C, 0) when results were obtained. The plates at time zero were stopped as previously
described above. Treated cells were returned to the incubator for 96 h at 37◦C and stored after fixation
with GBS in the refrigerator at 4◦C until required [27]. The T/C corr. values for the extracts were
calculated as described above.
Secondary Screening
Two-fold serial dilutions of the 50 mg/mL stock solution were made by diluting with DMSO to
obtain five stock dilutions. The stock solution was diluted 1:500 with the culture medium and 100 µl
were added to cells in 96-well plate as triplicates starting with the least concentration to the highest
concentration [27]. The plates were returned to the incubator for 96 h at 37◦C and the plates at time
zero were stopped with glutaraldehyde fixation. After incubation period, treated cells were handled as
described above and IC50 values of the extracts estimated.
5.9.2. Brine Shrimp Toxicity Assay (BSCA)
The toxic effect of DLEc and DSbEc on brine shrimp larvae was measured by using a previously
reported method [29,30].
5.9.3. Determination of Mechanism of Cytotoxic Action of Most Active Fractions on SiSo Cancer
Cell Line
Fractions 1H, 1I and 2E, 2F were selected for apoptotic and cell cycle analysis with the SiSo cell line.
Apoptosis Measurement
The induction of apoptosis of the fractions on SiSo cell line was determined by using an
Annexin-V/propidium iodide double staining, flow cytometric method as described previously [31].
Cell Cycle Analysis: Propidium Iodide (PI) Staining
The ability of the fractions to arrest the cell cycle progression in SiSo cell line was done by staining
cells with propidium iodide and measuring the phases of the cell cycle by flow cytometry as described
previously [32].
A summary of the extraction, fractionation and testing procedures is shown in Scheme 1.
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